A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder

Papakostas, George I., Fava, Maurizio, Canadian Journal of Psychiatry

Objective: To compare response rates among patients with major depressive disorder (MDD) treated with either moclobemide, an antidepressant thought to simultaneously enhance both noradrenergic and serotonergic neurotransmission, or selective serotonin reuptake inhibitors (SSRIs).

Methods: Using a random-effects model, we combined 12 trials involving 1207 outpatients with MDD.

Results: Patients treated with moclobemide were as likely to experience clinical response as those treated with SSRIs (risk ratio 1.08; 95% confidence interval, 0.92 to 1.26; P = 0.314). Simply pooling response rates for the 2 agents resulted in a 62.1% response rate for moclobemide and a 57.5% …

Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information: Article title: A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. Contributors: Papakostas, George I. - Author, Fava, Maurizio - Author. Journal title: Canadian Journal of Psychiatry. Volume: 51. Issue: 12 Publication date: October 2006. Page number: 783+. © Canadian Psychiatric Association Feb 2009. Provided by ProQuest LLC. All Rights Reserved.

This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.